Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has announced an update on its ongoing on-market share buy-back program, revealing that it repurchased 65,217 shares on the previous day, bringing the total number to 2,955,365 shares. This buy-back initiative is part of CSL’s broader strategy to optimize capital management, potentially enhancing shareholder value and reinforcing its market position in the pharmaceutical sector.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$188.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology and pharmaceutical industry, specializing in the development and delivery of innovative medicines and therapies. The company focuses on providing life-saving blood plasma products, vaccines, and biotherapeutics catering to global markets.
Average Trading Volume: 1,149,144
Technical Sentiment Signal: Sell
Current Market Cap: A$85.94B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.